Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:3973
Name thyroid gland medullary carcinoma
Definition A thyroid gland carcinoma that has_material_basis_in parafollicular cells.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer endocrine gland cancer thyroid gland cancer thyroid gland carcinoma thyroid gland medullary carcinoma

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown Cabozantinib thyroid gland medullary carcinoma not applicable detail...
Unknown unknown Vandetanib thyroid gland medullary carcinoma not applicable detail...
RET C634W Sorafenib thyroid gland medullary carcinoma sensitive detail...
RET M918T Cabozantinib thyroid gland medullary carcinoma sensitive detail...
RET mutant Everolimus thyroid gland medullary carcinoma sensitive detail...
RET C620R Everolimus thyroid gland medullary carcinoma sensitive detail...
RET M918T Everolimus thyroid gland medullary carcinoma sensitive detail...
Unknown unknown Lenvatinib thyroid gland medullary carcinoma not applicable detail...
RET C634W XMD15-44 thyroid gland medullary carcinoma sensitive detail...
RET C634W ALW-II-41-27 thyroid gland medullary carcinoma sensitive detail...
RET C634W HG-6-63-01 thyroid gland medullary carcinoma sensitive detail...
RET M918T HG-6-63-01 thyroid gland medullary carcinoma sensitive detail...
RET M918T XMD15-44 thyroid gland medullary carcinoma sensitive detail...
RET M918T ALW-II-41-27 thyroid gland medullary carcinoma sensitive detail...
RET positive Y078-DM4 thyroid gland medullary carcinoma sensitive detail...
RET M918T AZD1480 thyroid gland medullary carcinoma sensitive detail...
KDR pos RET C634W Motesanib thyroid gland medullary carcinoma predicted - sensitive detail...
RET mutant Cabozantinib thyroid gland medullary carcinoma sensitive detail...
HRAS mutant Cabozantinib thyroid gland medullary carcinoma sensitive detail...
Unknown unknown Sorafenib thyroid gland medullary carcinoma not applicable detail...
RET M918T Sorafenib thyroid gland medullary carcinoma predicted - sensitive detail...
RET C634R Sorafenib thyroid gland medullary carcinoma predicted - sensitive detail...
RET C634Y Sorafenib thyroid gland medullary carcinoma predicted - sensitive detail...
RET C634F Sorafenib thyroid gland medullary carcinoma predicted - sensitive detail...
RET C618R Sorafenib thyroid gland medullary carcinoma predicted - sensitive detail...
ATM L804fs ATM S978fs RET M918T Everolimus + Vandetanib thyroid gland medullary carcinoma predicted - sensitive detail...
RET C634W RXDX-105 thyroid gland medullary carcinoma sensitive detail...
RET C634W BLU-667 thyroid gland medullary carcinoma sensitive detail...
RET C609X N/A thyroid gland medullary carcinoma not applicable detail...
RET C611X N/A thyroid gland medullary carcinoma not applicable detail...
RET C618X N/A thyroid gland medullary carcinoma not applicable detail...
RET C620X N/A thyroid gland medullary carcinoma not applicable detail...
RET C630X N/A thyroid gland medullary carcinoma not applicable detail...
RET C634X N/A thyroid gland medullary carcinoma not applicable detail...
RET A883X N/A thyroid gland medullary carcinoma not applicable detail...
RET M918X N/A thyroid gland medullary carcinoma not applicable detail...
RET V804M RET E805K N/A thyroid gland medullary carcinoma not applicable detail...
RET V804M RET Y806C N/A thyroid gland medullary carcinoma not applicable detail...
RET V804M RET S904C N/A thyroid gland medullary carcinoma not applicable detail...
RET E768X N/A thyroid gland medullary carcinoma not applicable detail...
RET L790X N/A thyroid gland medullary carcinoma not applicable detail...
RET Y791X N/A thyroid gland medullary carcinoma not applicable detail...
RET V804X N/A thyroid gland medullary carcinoma not applicable detail...
RET S891X N/A thyroid gland medullary carcinoma not applicable detail...
RET L629P RET D631_R635delinsG RET V637R BLU-667 thyroid gland medullary carcinoma predicted - sensitive detail...
RET M918T BLU-667 thyroid gland medullary carcinoma predicted - sensitive detail...
RET mutant Selpercatinib thyroid gland medullary carcinoma sensitive detail...
RET V804M Selpercatinib thyroid gland medullary carcinoma sensitive detail...
RET M918T Selpercatinib thyroid gland medullary carcinoma sensitive detail...
RET C634W Selpercatinib thyroid gland medullary carcinoma sensitive detail...
RET V804M RET M918T Everolimus + Vandetanib thyroid gland medullary carcinoma resistant detail...
RET V804M RET M918T Selpercatinib thyroid gland medullary carcinoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT01396408 Phase II Temsirolimus Sunitinib A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours Active, not recruiting
NCT01838642 Phase II Ponatinib Ponatinib for Advanced Medullary Thyroid Cancer Terminated
NCT01896479 FDA approved Cabozantinib A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer Recruiting
NCT02657551 Phase II Regorafenib A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer Recruiting
NCT02831179 Phase I Capecitabine + Temozolomide + Veliparib Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Withdrawn
NCT02867592 Phase II Cabozantinib Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Recruiting
NCT02936323 PEN-221 PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers Active, not recruiting
NCT03037385 Phase I BLU-667 Phase 1 Study of BLU-667 in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors Recruiting
NCT03072160 Phase II Pembrolizumab Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer Completed
NCT03157128 Phase Ib/II Selpercatinib Phase 1/2 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)ET Activation (LIBRETTO-001)er Recruiting
NCT03780517 Phase I DS-5010 Safety, Efficacy, and Tolerability of BOS172738 in Patients With Advanced Rearranged During Transfection (RET) Gene-Altered Tumors Recruiting
NCT04106843 Phase II lutetium Lu 177 dotatate Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers Not yet recruiting
NCT04211337 Phase III Vandetanib Cabozantinib Selpercatinib A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531) Recruiting